Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This product is a **combination formulation** comprised of a gonadotropin-releasing hormone agonist (a class of peptide hormone drugs that target the gonadotropin-releasing hormone receptor to modulate reproductive hormone secretion), polyethylene glycol (an inert polymer often used to improve pharmacokinetics or solubility), and Rh760 (a near-infrared fluorescent dye, specifically in the context of FSH-Rh760, for imaging and photothermal therapy in oncology)[1]. While the specific formulation requested (gonadotropin-releasing hormone agonist + polyethylene glycol + Rh760) is not directly described in clinical literature, compounds containing Rh760 are used as targeted imaging agents, leveraging peptide conjugates (e.g. FSH peptide–Rh760) for **tumor-specific imaging and photothermal therapy**, particularly in ovarian cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gonadotropin-releasing hormone agonist + polyethylene glycol + Rh760.